iCardiac Technologies' Growth Accelerates Revenue Growth Exceeds 140% Supported By Expansion Of Operations
iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced recently it has recorded another increase in its growth rate. Revenues for the first half of fiscal 2012 increased by over 140% in comparison to revenues for the first half of fiscal 2011. The growth was supported by expansion of the operations in the US, Europe and Asia, with additions of experienced staff, technical infrastructure and facilities to ensure high quality of service.
“The revenue growth is a testament to both the highly scalable delivery architecture we have built as well as the superiority of our technologically differentiated services in the market place,” said Mikael Totterman, chief executive officer of iCardiac Technologies. “We have now clearly established ourselves as the largest dedicated provider of ECG and Holter cardiac safety studies and are proud of our focus on delivering customized cardiac safety solutions to our partners and customers.”
About iCardiac Technologies
iCardiac Technologies, Inc. is the world’s largest dedicated ECG core laboratory serving the pharmaceutical industry. iCardiac operates on an international scale with in-region staff members across North America, Europe, and Asia. Our global services include rapid 2-hour cardiology review of ECGs and Holters, data accessibility for study sponsors and CROs anytime, anywhere, and 24/7 in-house technical support for clinical sites globally. iCardiac’s iClinica platform maximizes the precision, accuracy, and decreases the cost of cardiac safety assessment from First-in-Human studies to Phase III studies including TQT studies. Our team of medical and scientific experts collectively has over 100 years of cardiology, electrophysiology, drug development, and regulatory expertise. iCardiac team members are key contributors to several FDA working groups that are advancing the field of cardiac safety.
SOURCE: iCardiac Technologies, Inc.